Alterity Therapeutics Ltd has released a press release.
Form F-3
Filed with ASX ·
On 6ix: 6ix.com/news/form-f-3
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- New commercial opportunity for PBT2
- Alterity presents at Finance News Network
- Prospectus filed pursuant to SEC Rule 424(b)(3)
- Chairmans Address 2020 Annual General Meeting
- US patent for next generation neurodegenerative diseases
Later from Alterity Therapeutics
- Dr David Stamler Appointed CEO
- Alterity participates in JP Morgan healthcare conference
- Michael J Fox grant for Parkinsons research on ATH434
- Alterity to present at Global Life Science Conference
- ATH434 protects brain cells and improves motor function
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics